P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE

P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE

Bibliographic Details
Main Authors:	Michael Roost Clausen, David Belada, Fritz Offner, Sven de Vos, Joshua Brody, Kim Linton, Sylvia Snauwaert, Raul Cordoba, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Lorenzo Falchi
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971360.55140.cd

Similar Items

P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE
by: M. R. Clausen, et al.
Published: (2022-06-01)

P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
by: Wojciech Jurczak, et al.
Published: (2023-08-01)

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: R. Cordoba, et al.
Published: (2022-06-01)

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
by: D. Belada, et al.
Published: (2022-06-01)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
by: Anna Sureda, et al.
Published: (2023-08-01)

Metabolic pitfall of pseudoprogression after epcoritamab treatment
by: Osamu Imataki, et al.
Published: (2024-12-01)

Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting
by: Clement D. Okello, et al.
Published: (2020-08-01)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
by: William Townsend, et al.
Published: (2023-07-01)

Study of the Λ(1116) interaction in cold nuclear matter
by: Arnold Oliver
Published: (2014-03-01)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
by: Andrew Grigg, et al.
Published: (2017-04-01)

Behaviour of brick-NHL render systems in presence of NaCl solution
by: Laura Falchi, et al.
Published: (2017-07-01)

Paippalādasaṃhitā 11.16: praskadvarī-, takvarī- and Atharvanic apām praśasti-
by: Tucker, E, et al.
Published: (2014)

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: B. E. Wahlin, et al.
Published: (2022-06-01)

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
by: Rumaisa Riaz, et al.
Published: (2023-07-01)

The Effects of New Accounting Standards on Firm Value: The K-IFRS 1116 Lease
by: Hae Jin Chung
Published: (2022-08-01)

Comparative structural analyses of the NHL domains from the human E3 ligase TRIM–NHL family
by: Apirat Chaikuad, et al.
Published: (2022-11-01)

SG-APSIC1116: Assessing COVID-19 symptoms in infected healthcare workers in Vietnam
by: Dinh Thi Thu Huong, et al.
Published: (2023-02-01)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
by: Benoit Tessoulin, et al.
Published: (2023-08-01)

Environmental management activities of NHL teams
by: Laura Márton
Published: (2022-06-01)

Environmental management activities of NHL teams
by: Laura Márton
Published: (2022-06-01)

The TRIM-NHL protein NHL-2 is a co-factor in the nuclear and somatic RNAi pathways in C. elegans
by: Gregory M Davis, et al.
Published: (2018-12-01)

Hit a new high
by: Gu Jianguo, et al.
Published: (2008-01-01)

Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells
by: Yao Wang, et al.
Published: (2011-01-01)

1116 VAX014 as a novel oncolytic agent for STING and RIG-I-positive solid tumors
by: Matthew Giacalone, et al.
Published: (2023-11-01)

Hydroxypropyl-β-Cyclodextrin Complexes of Styryllactones Enhance the Anti-Tumor Effect in SW1116 Cell Line
by: Ru Ma, et al.
Published: (2020-04-01)

NHL25 and NHL3, Two NDR1/HIN1-Like Genes in Arabidopsis thaliana with Potential Role(s) in Plant Defense
by: Anne Varet, et al.
Published: (2002-06-01)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
by: Allison Rosenthal, et al.
Published: (2023-08-01)

P1127: FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL
by: Emma Verner, et al.
Published: (2023-08-01)

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes
by: John F. Seymour, et al.
Published: (2014-08-01)

Epidemiology, causes, evolution and outcome in a single-center cohort of 1116 critically ill patients with hypoxic hepatitis
by: Astrid Van den broecke, et al.
Published: (2018-01-01)

1116 Long-term ocular safety of hydroxychloroquine in patients with childhood-onset SLE (cSLE) followed into adulthood
by: Wei Chen, et al.
Published: (2021-11-01)

Salivary Gland NHL – An FNAC–Flow Cytometry Study
by: Rashmi Gautam, et al.
Published: (2024-04-01)

Born at the wrong time: selection bias in the NHL draft.
by: Robert O Deaner, et al.
Published: (2013-01-01)

NHL Heavyweights: Narratives of Violence and Masculinity in Ice Hockey
by: Tjønndal Anne
Published: (2016-06-01)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
by: LI Caixia, et al.
Published: (2023-08-01)

Nilai U, UPM hit another high
by: New Straits Times,
Published: (2015)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
by: Chang-Ju Qu, et al.
Published: (2023-08-01)

P11.16 BLOOD PRESSURE VARIABILITY IS ASSOCIATED WITH AORTIC STIFFNESS AND TROPONIN-T IN PATIENTS WITH CKD STAGES 3 AND 4
by: L.A. Tomlinson, et al.
Published: (2011-11-01)

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)
by: Masahiro Yokoyama, et al.
Published: (2021-04-01)

Tramp iron in chopped hay: Electronic device detects and removes bits of iron from chopped hay pneumatically conveyed at high speeds
by: J Dobie, et al.
Published: (1953-09-01)